TNFRSF17 and Miyoshi myopathy: In case of disease re‐progression after anti‐BCMA CAR‐T therapy, the MM cell percentages in the bone marrow and M protein levels in peripheral blood of R/R MM patients with EM‐E are not necessarily consistent with further disease progression.